| 000 | 01425 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250515090852.0 | ||
| 264 | 0 | _c20071212 | |
| 008 | 200712s 0 0 eng d | ||
| 022 | _a0077-8923 | ||
| 024 | 7 |
_a10.1196/annals.1423.049 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMareckova, Helena | |
| 245 | 0 | 0 |
_aNatalizumab in the treatment of patients with multiple sclerosis: first experience. _h[electronic resource] |
| 260 |
_bAnnals of the New York Academy of Sciences _cSep 2007 |
||
| 300 |
_a465-73 p. _bdigital |
||
| 500 | _aPublication Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aCD4-Positive T-Lymphocytes _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xcerebrospinal fluid |
| 650 | 0 | 4 | _aNatalizumab |
| 650 | 0 | 4 |
_aReceptors, CCR5 _xmetabolism |
| 650 | 0 | 4 |
_aReceptors, CXCR3 _xmetabolism |
| 700 | 1 | _aHavrdova, Eva | |
| 700 | 1 | _aKrasulova, Eva | |
| 700 | 1 | _aVankova, Zdenka | |
| 700 | 1 | _aKoberová, Michaela | |
| 700 | 1 | _aSterzl, Ivan | |
| 773 | 0 |
_tAnnals of the New York Academy of Sciences _gvol. 1110 _gp. 465-73 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1196/annals.1423.049 _zAvailable from publisher's website |
| 999 |
_c17433110 _d17433110 |
||